# Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

> **NCT06561022** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 260 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Everolimus
- **DRUG:** Fulvestrant
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT06561022
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-21
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561022, "Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06561022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*